Quick Answer
Guardant Health, Inc. reported Research And Development Expense of $364.19 million for the year ending 2025.
- Guardant Health, Inc. showed an increase of +4.7% in Research And Development Expense from 2024 to 2025.
- This data is from Guardant Health, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Guardant Health, Inc.'s Research And Development Expense has grown by 3,253.8%.
- Historical annual values: Fiscal year 2025: $364.19 million | Fiscal year 2024: $347.75 million | Fiscal year 2023: $367.19 million | Fiscal year 2022: $373.81 million | Fiscal year 2021: $263.22 million | Fiscal year 2020: $149.86 million | Fiscal year 2019: $86.29 million | Fiscal year 2018: $50.71 million | Fiscal year 2017: $25.56 million | Fiscal year 2016: $10.86 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: